1 Yale University School of Medicine New Haven, Connecticut 06510
In his recent Commentary (Pediatrics, 45:191, 1970)on prognosis of childhood leukemia, the prime evidence cited by Dr. Holland to indicate significant improvement in survival due to vigorous antileukemic chemotherapy, is the performance of children in "Regimen D of AGLB, protocol 6601." He asserts "seventy-five percent of these children re alive at 24 months." The survival data plotted on his Figure 1 also indicate no deaths in the first year of therapy. These apparently remarkable therapeutic results become less impressive when the legend of Figure 1 is examined.